BridgeMD
RUBIKID - Dynamic 82-Rb positron emission tomography (PET) for the grading of KIDney carcinoma
EU CTIS ID: 2024-514085-39-00
What this study is testing
To test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC on histology (ISUP grades), i.e., to successfully identify high-grade (ISUP grades 3 and 4) vs. low-grade (ISUP grades 1 and 2) RCC.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18 years old
- Signed written informed consent
- French Social Security affiliation
- Patients with high suspicion of or confirmed RCC requiring surgical resection
- Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA)
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
You likely can't join if
- Pregnant or breastfeeding women
- Bosniak 3 cysts
- Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA
- Exclusion of clear renal cell adenocarcinoma on biopsy
- Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).
- Patient under legal protection (guardianship)
See the full eligibility criteria
- Age ≥ 18 years old
- Signed written informed consent
- French Social Security affiliation
- Patients with high suspicion of or confirmed RCC requiring surgical resection
- Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA)
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- Pregnant or breastfeeding women
- Bosniak 3 cysts
- Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA
- Exclusion of clear renal cell adenocarcinoma on biopsy
- Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).
- Patient under legal protection (guardianship)
- Contraindication to the PET-CT
- Contraindication to the injection of 82-Rb
- Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable
- Patient on SMA (state medical aid)
- Unilateral renal agenesis
- Multicystic renal dysplasia
- Hereditary forms of RCC as VHL, MET, FH and FLCN
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.